Viatris
Global healthcare company
VTRS Nasdaq
ISIN US92556V1061 SEC CIK 1792044 LEI 254900ZZTSW7NL773X71
Follow Viatris
Weekly email: filings, results
Revenue, last quarter
$3.7B
−0.3% vs same quarter last year
Net income
−$325.3M
−153.7% vs same quarter last year
EPS, diluted
−$0.28
−154.5% vs same quarter last year
Operating cash flow
$899.4M
+20.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $14.3B | −$3.5B |
| FY24 | $14.7B | −$634.2M |
| FY23 | $15.4B | $54.7M |
| FY22 | $16.2B | $2.1B |
| FY21 | $17.8B | −$1.3B |
| FY20 | $11.8B | −$669.9M |
| FY19 | $11.4B | $16.8M |
| FY18 | $11.3B | $352.5M |
| FY17 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 35.2% | −18.7% | −24.7% |
| FY24 | 38.3% | 0.1% | −4.3% |
| FY23 | 41.8% | 5% | 0.4% |
| FY22 | 40.1% | 10% | 12.8% |
| FY21 | 31.3% | −0.2% | −7.1% |
| FY20 | 32.1% | −1.8% | −5.7% |
| FY19 | 34.3% | 6.3% | 0.1% |
| FY18 | 35.5% | 8% | 3.1% |
| FY17 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $1.9B |
| FY24 | $2B |
| FY23 | $2.5B |
| FY22 | $2.6B |
| FY21 | $2.6B |
| FY20 | $988.8M |
| FY19 | $1.6B |
| FY18 | $2.1B |
| FY17 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $500.5M |
| FY24 | $250M |
| FY23 | $250M |
| FY22 | $0 |
| FY21 | $0 |
| FY20 | $0 |
| FY19 | $0 |
| FY18 | $432M |
| FY17 | - |
- Viatris
- Healthcare median
Show the numbers
| Year | Viatris | Healthcare median |
|---|---|---|
| FY25 | −24.7% | −30.6% |
| FY24 | −4.3% | −47% |
| FY23 | 0.4% | −58% |
| FY22 | 12.8% | −80.4% |
| FY21 | −7.1% | −71.9% |
| FY20 | −5.7% | −62.2% |
| FY19 | 0.1% | −46.3% |
| FY18 | 3.1% | −49.6% |
| FY17 | - | −45.9% |